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Abstract
One of the most common complications of fibrous dysplasia of bone (FD) is bone pain. Usual pain killers are often of
inadequate efficacy to control this bone pain. The mechanism of bone pain in FD remains uncertain, but by analogy
with bone tumors one may consider that ectopic sprouting and formation of neuroma-like structures by sensory and
sympathetic nerve fibers also occur in the dysplastic skeleton. Bone pain has been reported in up to 81% of adults
and 49% of children. It affects predominantly the lower limbs and the spine. The degree of pain is highly variable and
adults reports more pain than children. Bisphosphonates have been shown to reduce bone pain in uncontrolled
studies. Their influence on bone strength remains unknown. In a randomized trial testing alendronate, bone pain was
not significantly improved. Another trial assessing the effect of risedronate is ongoing. Possible future therapies
include tocilizumab, denosumab and drugs targeting nerve growth factor and its receptor TrkA.
Introduction
Fibrous dysplasia of bone (FD) is a rare disease responsible
for bone deformities, fractures, nerve compression and
bone pain. There are specificities in the pathophysiology
of bone pain compared to other tissues, including the role
of increased bone resorption. The treatment of bone pain
can involve non specific drugs and bone-specific drugs,
such as bisphosphonates.
We will review the pathophysiology of bone pain, the
current therapeutic possibilities and the treatment
perspectives.
Pathophysiology of bone pain
Pain is a common occurrence in FD and is often the pre-
senting symptom of the disease [1-3]. When the health-
related quality of life was assessed in FD subjects, both
adults and children had significantly more skeletal pain
than the U. S. population [4]. A common misconception
is that FD pain dissipates with age; however, recent
population studies suggest that FD pain actually increases
with age [3]. The analgesics that are most commonly
used to control FD pain are non-steroidal anti-inflamma-
tory drugs (NSAIDS), bisphosphonates and opiates [2,3].
However, lack of recognition by the medical community
that FD pain can be both severe and increase in adult-
hood has led many FD patients to be labeled as “drug
seeking” and inadequately treated [3]. Adequate pain
management of FD pain, like nearly all other types of
pain, is clearly required for FD patients to maintain their
functional status and quality of life.
Currently, our understanding of the factors that drive
FD pain and how to best treat FD pain comes mainly
from empirical studies concerning the ability of available
therapies to relieve FD pain. Two seminal clinical studies
included one where it was demonstrated that FD pain
was attenuated following infusion of the bisphosphonate
pamidronate [5]. The second showed that there was not
a clear correlation between FD pain and disease burden,
and that in terms of frequency and severity FD pain
increases with age [3]. This later finding may in part be
explained by the fact that whereas bone mass, density,
and strength all decline with age, sensory nerve fibers
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transmit this information to the spinal cord and brain, do
not appear to decline with age [6].
W h i l et h e r ea r ec u r r e n t l yn odirect studies examining
what mechanisms drive FD pain, in the last decade signif-
icant strides have begun to be made in understanding the
specific populations of sensory nerve fibers that innervate
the skeleton [7,8], what mechanisms drive malignant and
non-malignant skeletal pain [9], what molecules prefer-
entially excite nerve fibers that innervate the bone [9],
and what analgesic therapies may be particularly effica-
cious in alleviating skeletal pain [10].
A select population of sensory nerve fibers
innervates the skeleton and drives skeletal pain
Bone is primarily innervated by thinly myelinated sensory
nerve fibers (A-delta) and peptide-rich CGRP
+ nerve
fibers and thus has less “redundancy” than is found in
skin. These nerve fibers may express the high affinity
nerve growth factor (NGF) receptor, Trk A, which med-
iates the multiple effects of NGF, including neuronal dif-
ferentiation and survival. That pattern of innervation is
present in the periosteum, mineralized bone, and marrow
[7,8] (Figure 1). These results suggest that this differential
population may provide a unique therapeutic opportunity
for developing novel analgesics that can attenuate FD
skeletal pain as fewer populations of nerve fibers will be
needed to be blocked to attenuate bone compared to skin
pain.
Sensory nerve fibers that innervate the skeleton can
undergo a remarkable sprouting and pathological
reorganization which may drive FD pain
One possible explanation as to why there is not a direct
correlation between disease burden and FD pain is that it
is not bone remodeling alone that drives bone pain, but
that sensory nerve fibers themselves also have to undergo
a pathological change. Recently, it has been shown that
when osteosarcoma cells are confined and grow within the
bone, there is a remarkable and ectopic sprouting and for-
mation of neuroma-like structures by sensory and sympa-
thetic nerve fibers in the skeleton (Fig. 2). Interestingly,
sustained administration of an anti-NGF sequestering
therapy blocked the pathological sprouting of sensory and
sympathetic nerve fibers, the formation of neuroma-like
structures, and significantly attenuated the generation and
maintenance of cancer pain in this model [11].
A major question is whether this ectopic sprouting of
sensory nerve fibers only occurs when cancer cells express
high levels of NGF. However, studies using canine prostate
cancer cells, that do not express detectable levels of NGF
[12] – as is observed in FD – simultaneously induce
Figure 1 Most sensory nerve fibers that innervate the bone express TrkA whereas fewer than 30% of the nerve fibers that innervate
the skin express TrkA. The skin is innervated by thickly myelinated A-beta fibers (TrkA
-), thinly myelinated A delta fibers (both TkA
- and TrkA
+),
unmyelinated peptide-rich C fibers (TrkA
+) and unmyelinated peptide-poor C-fibers (TrkA
-). In contrast, the bone appears to be predominantly
innervated by thinly myelinated A-delta fibers (TrkA
- but mostly TrkA
+) and peptide-rich C-fibers (mostly TrkA
+ and a small proportion TrkA
-). As
greater than 80% of all sensory nerve fibers that innervate the bone are TrkA
+ whereas only 30% of the sensory nerve fibers that innervate skin
are TrkA
+, these data might help explain why blocking NGF or its cognate receptor TrkA appears to be more efficacious in attenuating skeletal
vs. skin pain.
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(Fig. 3). A similar ectopic sprouting of sensory and sympa-
thetic nerve fibers occurs in the bone marrow and minera-
lized bone [13]. As these prostate cells do not express
detectable levels of mRNA coding for NGF, these data
suggest that this ectopic sprouting of nerve fibers is not
primarily driven by NGF released from tumor cells, but
rather by the major source of NGF arising from endogen-
ous stromal, inflammatory and immune cells [14,15].
These newly sprouted nerve fibers are probably also acti-
vated and sensitized by released NGF and as such this
truly ectopic and pathological reorganization of sensory
and sympathetic nerve fibers may provide an anatomical
substrate which drives skeletal pain. In support of this
hypothesis, preventive treatment with an antibody that
sequesters NGF, administered when prostate tumor-
induced pain and bone remodeling were first observed,
blocked this ectopic sprouting and significantly inhibited
the development and severity of cancer pain [13].
While it is not known whether sprouting of sensory
nerve fibers occurs in FD, this phenomenon has been
observed in non-malignant skeletal pain states in human
and animals. Previous studies have reported that human
chronic discogenic pain may in part be due to a growth
of TrkA
+ nerve fibers into normally aneural and avascu-
lar areas of the human intervertebral disc [16]. Other stu-
dies have demonstrated significant sprouting of CGRP
+
nerve fibers following bone fracture in rat and in the
arthritic joints of humans and animals [17-19]. These
reports suggest that following injury or disease of the
skeleton, significant sprouting of TrkA
+ nerve fibers can
occur, and it appears that endogenous stromal cells as
well as inflammatory and immune cells are the source of
NGF [14,15].
The burden of bone pain in fibrous dysplasia
Methods and patients (adapted from Ref. 4)
We have studied a relatively large population of patients
with FD in an effort to understand their experience with
pain [4]. All subjects enrolled in a National Institutes of
Health (NIH) Institutional Review Board approved study
of FD and MAS were invited to complete the self report
Brief Pain Inventory (BPI) and a demographic data ques-
tionnaire during their initial evaluation at NIH between
July 2000 and July 2005. Ninety-one subjects were enrolled
during that period, and 78 (86%) completed the pain form
and had a
99Tc-MDP bone scan, including 56 subjects
14 or older (72%) and 22 under the age of 14 (28%). The
Figure 2 Sprouting and formation of neuroma-like structures in chronic bone pain. Sarcoma tumor cells expressing green fluorescent
protein (green) induce a marked sprouting and neuroma formation of CGRP
+ sensory nerve fibers (red) that innervate the bone (white). These
nerve fibers detect and transmit painful stimuli from periphery to the central nervous system. A) In sham bones, CGRP
+ nerve fibers that are
present in the bone appear as single nerve fibers with a liner and homogenous morphology. B) As cancer cells proliferate and grow in bone,
these induce significant bone remodeling (pitted appearance) as well as a highly pathological sprouting and formation of neuroma-like
structures by sensory and sympathetic nerve fibers which in other conditions drives chronic pain. Confocal images from periosteal whole
preparations were acquired and overlapped on a three dimensional image of the mouse femur obtained by microcomputed tomography.
Images were rendered courtesy of Marvin Landis (University Information Technology Services, University of Arizona).
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clinical history, histopathological findings, radiographic
findings, and when necessary, an analysis of the GNAS
gene for R201 mutations. Bone scans were assessed for
sites of FD involvement, which were identified as areas of
non-physiologic tracer uptake, and disease severity was
determined using a validated scoring tool [20]. The fact
that tracer uptake sites represented FD was confirmed by
radiograph and/or CT. Pain was assessed using a human
figure drawing and the numeric rating scale (NRS) of the
Brief Pain Inventory (BPI). The BPI is a short, self-adminis-
tered questionnaire developed to assess the severity and
impact of pain primarily in cancer patients [21]. It has
been shown to be valid and reliable in adults when used to
assess cancer pain [21], chronic and acute nonmalignant
pain and pain in osteoarthritis patients. The goal was to
assess pain “intrinsic” to the FD and not pain that occurred
in relation to a fracture. Therefore, acute or healing frac-
tures were excluded from the analysis (i.e., > 6 months
since radiographic evidence of complete healing at a site at
which there had been a recent fracture). Analgesic use and
perceived relief information was obtained as part of the
questionnaire, and confirmed during patient interviews.
Results
The study population was made up of a group of subjects
with a broad spectrum of disease, from isolated monosto-
tic FD, to total skeletal involvement. The lower extremities
w e r et h es i t e sm o s tl i k e l yt ob ea f f e c t e db yF D( 8 6 %o f
adults, 97% of children, p=NS for differences between
adults and children). The head was also commonly
affected (86% of adults, 94% of children, p=NS). FD lesions
were found less frequently in the upper extremities (72%
of adults, 89% of children, p=NS), the ribs (72% of adults,
57% of children, p=NS) and the spine (72% of adults, 46%
of children, p<0.05). The spine was the only site at which
there was a significant increase in FD involvement over
time.
Pain was prevalent in the FD population; 67% reported
pain at FD sites. Pain was more common in adults than
children, and was reported by 81% of adults and 49% of
children (p<0.005) (Fig. 4). Adults reported significantly
more pain than children in both the lower extremities
(adults 81%, children 53%, p<0.05) and the spine (adults
52%, children 13%, p<0.05) (Figure 2). The degree of
pain reported was considerable, but quite variable. The
mean pain score (on the 0 to 10 pain scale) for adults
was 4.1 (range 1 to 8, ± 1.8), and 2.8 for children (range
1 to 7, ± 1.8) (Table 1). Adults had significantly more
pain than children (p<0.01). In an effort to assess how
pain prevalence changed with aging, we examined the
prevalence of pain in age group increments of 10 years.
No pain was reported by children less than 10 years old,
while 50-60% of those age 11 through 30 reported pain
and 85-100% of the patients over 31 years of age experi-
enced pain (Table 1).
There was no correlation between pain prevalence and
gender, phosphate wasting, vitamin D status (serum vita-
min D level < 32 ng/ml was used as a cutoff for the diag-
nosis of vitamin D deficiency), or any endocrinopathy in
children. Growth hormone excess correlated with pain
prevalence at FD sites in adults (p=0.031).
Figure 3 Prostate cancer cells induce sprouting of sensory nerve fibers in the bone marrow of tumor bearing femurs. High power µCT
slices of bone (100 µm-thick) overlaid with confocal images (20 µm-thick) obtained from a sham femur (A) and tumor-bearing femur from mice
sacrificed at early (B) and more advanced stages of the disease (C). In these images the DAPI stained nucleus of cells appear blue, the green
fluorescent protein expressing (GFP) prostate cancer cells appear green, and the calcitonin gene related peptide (CGRP) sensory nerve fibers
appear yellow/red. Note that in the sham mice, CGRP
+ nerve fibers that are present in the marrow space of normal mice appear as single, nerve
fibers with a highly linear morphology. As GFP
+ prostate tumor cells proliferate and form tumor colonies (B,C), the CGRP
+ sensory nerve fibers
undergo marked sprouting which produces highly branched, disorganized and dense meshwork of sensory nerve fibers (B,C) that is never
observed in the normal marrow (A).
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trol pain (Table 2). NSAIDs were most commonly used
(57% of adults and 56% of children who had pain).
Some subjects reported using more than one treatment.
There was a trend for children who reported pain to be
less likely to be treated for pain than adults (p=0.21).
Treatment of fibrous dysplasia bone pain with
bisphosphonates
The use of an antiresorptive agent in the treatment of an
osteoblastic lineage disease, such as FD, is counterintuitive.
The rationale for doing so is based on the presence of
abundant osteoclastic bone resorption within and around
the fibrous tissue. Therefore, in an early study that took as
an example the treatment of Paget’s disease, 9 patients
Figure 4 Prevalence of pain at skeletal sites involved with fibrous dysplasia in adults and children. Sites at which patients reported pain
was recorded. 99Tc-MDP bone scans were reviewed to confirm the presence of FD at the reported site of pain. Only those sites at which there
was a concordance of pain and FD involvement were recorded. Adults had significantly more pain than children in general (p<0.05), and at
both the lower extremity and the spine (p<0.05 for both).
Table 1 Prevalence of pain by age groups
Age group (years) n % of subjects with pain
<10 7 0
11-20 27 59
21-30 10 50
31-40 13 85
41-50 14 100
>50 7 86
Table 2 Pain severity, treatment and response to
treatment
1
Adults Children
Average pain 4.1* 2.8
Treatment %
treated
% with
releif
%
treated
% with
releif
No treatment 26% 44%
NSAIDs 57% 56% 56% 50%
Narcotics 26% 47% 17% 90%
Bisphosphonates 26% 73% 17% 75%
Alternative
Treatments
17% 52% 11% No report
1Only subjects who had FD-associated pain are recoded in this analysis.
*=p<0.05, NSAIDs = non steroidal anti-inflammatory drugs
Figure 4 and Tables 1 and 2 reprinted with permission from the National
Osteoporosis Foundation, Washington, DC 20036. Osteoporosis Int (2008)
19:57-63: All rights reserved.
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6 months), with striking radiographic improvements and
decreases in bone pain and biochemical markers of bone
remodeling [5]. Patients were also receiving calcium (500-
1500 mg/day) and vitamin D (800-1200 IU/day)
supplements.
Long-term effects of this regimen have been assessed
with additional patients and longer follow-up, still in an
open design, with similar results [2,22]. A dose of 3 mg/
kg/treatment cycle was used in children and adolescents,
who represented 30% of this cohort. Fifty-eight patients
have been treated with intravenous pamidronate and fol-
lowed-up for an average 50 months (ranging from 1 to 11
years). Pain intensity was reduced after the first course of
treatment, with an additive effect observed after several
treatment cycles. Bone pain disappeared in 60% of these
patients, diminished in 24% and did not improve in 16% of
them. In parallel, biochemical markers of bone turnover –
such as total alkaline phosphatase, serum osteocalcin, and
urinary CTX – were also significantly reduced compared
to baseline. Half of those treated patients had discernable
radiological improvement, characterized by filling of osteo-
lytic lesions and/or cortical thickening. In addition, total
hip bone mineral density (BMD) measured in patients
who had hip involvement was substantially increased [23].
Results were similar in adults and children or adolescents.
These biochemical and radiological changes, however,
were not associated with bone pain reduction.
Favorable outcomes have also been observed in other
open studies using intravenous pamidronate, administered
at 6-month intervals. Thus, bone pain was significantly
relieved in a study involving 7 patients with various forms
of FD treated with intravenous pamidronate [24]. A
greater increase in BMD was also observed in affected
areas than in unaffected areas, using whole body DXA to
compare the affected to the unaffected side, after 1 year of
treatment. Simultaneously, the level of bone turnover as
assessed by biochemical markers was reduced but most
patients still had increased bone turnover.
A few patients have also been treated successfully with
alendronate. For example, an increase of 158% in total
hip BMD over 2 years has been observed in a 22-year old
woman who had received four 90 mg infusions of pami-
dronate every 4 weeks, followed by oral alendronate
10 mg/day [25], with a parallel relief in bone pain and
decrease in urinary NTX. In another case report [26], a
45-year old woman who received alendronate 5 mg/day
was relieved of her bone pain after several months of
treatment. Bone turnover was diminished and the radi-
ological appearance improved slightly. In a series of 6
adult patients who had been treated with pamidronate
followed by alendronate or who had used alendronate
alone, bone pain decreased substantially in response to
therapy, bone resorption was reduced with intravenous
pamidronate but not with oral alendronate, and four out
of six patients exhibited radiological improvement [27].
Although most patients respond favorably to pamidro-
nate therapy, a subset (15% in our group’se x p e r i e n c e ,
RDC) did not exhibit any improvement in bone pain.
Other patients, with an initial positive response to treat-
ment with pamidronate, have suffered from a relapse of
bone pain or failed to maintain reduced levels of biochem-
ical markers of bone turnover. When those patients who
relapsed or failed treatment with pamidronate were
switched to zoledronic acid, we were not able to obtain
significant reductions in bone pain or improvement in the
radiographic appearance [28]. Zoledronic acid was well-
tolerated, with only two patients with an acute phase reac-
tion associated with the first infusion. Those patients
switched to zoledronic acid tended to have more serious
disease than the other patients on pamidronate only.
In another study [29], however, no convincing evidence
of radiographic benefit could be observed in 18 children
and adolescents with polyostotic FD, despite significant
reduction in levels of bone turnover markers. The expla-
nation for the discrepancy between this study conducted
in young patients and those in adults or other pediatric
series [30-32] remains unclear, but some of the difference
might relate to the absence of use of phosphate supple-
ments in those patients with renal phosphate wasting.
The difference may also stem from the difficulty in defin-
ing appropriate radiographic outcomes in studies of FD,
as lesions are heterogeneous and radiographs are not
always reproducible over time.
All these results were obtained in uncontrolled open
studies. The role of the placebo effect and regression to
the mean is likely to explain some of the effect on bone
pain. The radiologic effect might be confounded by the
age-related sclerosis of lesions [33], but this phenomenon
arises over long periods of time, whereas the improvement
associated with bisphosphonate use could be observed
over shorter periods of time, e.g., 2-3 years. These short-
comings led to the design of two randomized placebo-con-
trolled clinical trials, one conducted in the USA to test
alendronate [34], and the other in Europe, the PROFIDYS
trial, testing risedronate [35]. The results of the first trial
are not yet published, and the latter is still recruiting
patients.
Perspectives
Some patients fail to respond to bisphosphonates or
relapse after an initial improvement in bone pain. These
individuals do not seem to respond better to more
potent bisphosphonates, such as zoledronic acid [28].
Those patients often have severe polyostotic disease,
with a history of several fractures, substantial bone pain,
and sometimes optic nerve compression. There is no
current satisfactory therapeutic option in these severely
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bisphosphonates.
We know that GNAS mutations result in abnormal
proliferation and differentiation of bone marrow stromal
cells. In those osteoblastic cells, IL-6 secretion is
increased as a result of Gs activation, with consequent
activation of surrounding osteoclasts, allowing the FD
lesion to expand and create osteolytic lesions [36]. A
direct link has been established between the GNAS
mutation in stromal cells and IL-6 production, so that
FD, which is an osteoblastic lineage disorder, is also
often associated with a hyperosteoclastic component
[37].
This is the rationale to selectively inhibit the IL-6 dri-
ven increased bone resorption that is observed in FD by
targeting the IL-6 receptor with tocilizumab, in those
patients who fail to respond to bisphosphonates primar-
ily or secondarily. Tocilizumab - a human monoclonal
antibody to IL-6 receptor - is a drug currently used in
rheumatoid arthritis (RA) treatment. It can reduce
symptoms, and block localized periarticular bone loss
induced by the disease. A recent study has also shown
that the level of systemic bone resorption, as assessed by
markers such as serum ICTP and CTX could be signifi-
cantly decreased in RA in response to tocilizumab [38].
Therefore, a randomized placebo-controlled cross-over
trial testing the value of tocilizumab to decrease bone
resorption among patients with FD who do not respond
to bisphosphonate therapy will be launched in Europe in
2011. A total of 12 patients will receive either tocilizumab
during 6 months followed by 6 months of placebo (6
patients), or 6 months of placebo followed by 6 months
of tocilizumab (6 patients). The study is powered to show
a 30% difference in bone resorption between the two
treatments. Decrease in bone resorption (primary end-
point) will be assessed with serum CTX. Secondary end-
points will be: decrease in bone pain, assessed by visual
analogic scale in the most painful skeletal site, decrease
in other markers of bone remodeling (serum osteocalcin,
bone alkaline phosphatase, P1NP), and improvement in
the short-form 36 (SF-36) quality of life scale.
Another way to develop new therapies to treat pain
associated with fibrous dysplasia is to understand the
unique populations of nerve fibers that innervate bone
and the mechanisms by which these nerve fibers signal
skeletal pain. Unlike skin, the majority of sensory nerve
fibers in bone express TrkA, TRPV1 antagonists, inhibi-
tors of CSFR1 and pregabalin (Table 3). In addition to
assessing the efficacy of these therapies to reduce FD
pain, endpoints which need to be included in these
Table 3 Therapies that may be useful in treating FD pain
CURRENT AND POTENTIAL THERAPIES FOR TREATMENT OF FIBROUS DYSPLASIA PAIN
DRUG CLASS TARGET ACTION POTENTIAL COMPLICATIONS
Current therapies
Biphosphonates Osteoclasts Osteoclast apoptosis Inhibition of bone remodeling/
Osteoclast activity suppression growth
Osteonecrosis
Opioids CNS neurons Stimulates opioid receptors Sedation
Dependence
Constipation
NSAIDS Prostaglandin synthesis Blockade of peripheral and central
sensitization
GI toxicity
Cardiotoxicity
Nephrotoxicity
Recently approved therapies/ ongoing clinical trials for treating other skeletal pain states
Denosumab (OPG) Blocks RANKL Blocks osteoclast activation Inhibition of bone remodeling/
(Amgen) growth
Osteonecrosis
Tanezumab (anti-NGF)
(Pfizer)
NGF/TrkA pathway Blockade of peripheral sensitization
Blockade of nerve sprouting
Developing sensory and sympathetic
nerve fibers
Potential therapies
NGF/TrkA inhibitors (Array, JNJ, Abbott) NGF/TrkA pathway Blockade of peripheral sensitization
Blockade of pH sensitive neurons
Developing sensory and sympathetic
nerve fibers
TRPV1 antagonists (Pfizer, JNJ, Abbott,
Merck, GSK, etc.)
TRPV1 channel Blockade of pH sensitive neurons Hyperthermia (transient?)
CSFR1 inhibitors response (Plexxikon,
Roche, JNJ)
Inhibition of CSFR1 Reduction in osteoclasts,
macrophages, etc.
Decreased immune response to
infection
Pregabalin (Pfizer) Calcium channel, a2, δ1
subunit
Aberrant neuronal discharge Lethargy
Drowsiness
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profile and risk/benefit to the patient. Additionally, devel-
oping an animal model of FD and understanding how the
density, morphology, phenotype, and response character-
istics of skeletal sensory nerve fibers changes in a pre-
clinical model of FD may help in the development of
more targeted therapies to treat FD pain.
Denosumab is currently approved to treat osteoporosis
as it targets RANKL and is remarkably effective at redu-
cing osteoclast-induced bone remodeling. As such it may
represent a potential treatment for FD bone pain. Prega-
balin has been shown to attenuate a wide variety of neu-
ropathic pain (i.e. pain originating from damaged or
ectopic reorganization of nerve fibers) and as ectopic
reorganization of nerve fibers may play an important role
in driving FD induced skeletal pain, pregabalin might be
useful in reducing FD pain, however no clinical study
data currently exists that specifically investigates the
efficacy of pregabalin in FD.
Conclusion
Bone pain is commonly observed in FD. Bisphospho-
nates can provide some relief of bone pain, but the
development of mechanism-based therapies to treat
neuropathic bone pain or the bone disease itself is
needed to improve the management of FD patients.
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